SCHEMBL11970631

SCHEMBL11970631

CCOC(=O)c1nn(-c2ccnc(N)n2)c2cc(Br)ccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ELANE P08246 9/20 0.46
▸ MAP3K14 Q99558 2/20 0.43
▸ CDC7 O00311 1/20 0.43
▸ CDK2 P24941 1/20 0.43
▸ ROCK1 Q13464 2/20 0.41
▸ PDGFRA P16234 1/20 0.40
▸ CDK5 Q00535 1/20 0.40
▸ TYRO3 Q06418 1/20 0.40
▸ TBK1 Q9UHD2 1/20 0.39
▸ ADORA1 P30542 2/20 0.39
▸ GABRG2 P18507 1/20 0.39
▸ GABRB3 P28472 1/20 0.39
▸ GABRA5 P31644 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ F2 P00734 1/20 0.39
▸ PLAU P00749 1/20 0.39
▸ ADORA3 P0DMS8 1/20 0.39
▸ ADORA2A P29274 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11970544 0.84 MAP3K14 (0.49) MAP3K14CDC7CDK2ROCK1PDGFRA
SCHEMBL11971129 0.84 MAP3K14 (0.49) MAP3K14CDC7CDK2ROCK1PDGFRA
SCHEMBL11971201 0.82 MAP3K14 (0.46) MAP3K14CDC7CDK2ROCK1PDGFRA
SCHEMBL11971511 0.82 MAP3K14 (0.46) MAP3K14CDC7CDK2ROCK1PDGFRA
SCHEMBL11970974 0.79 MAP3K14 (0.53) MAP3K14CDC7CDK2ROCK1PDGFRA
SCHEMBL11970447 0.78 MAP3K14 (0.45) MAP3K14CDC7CDK2ROCK1PDGFRA
SCHEMBL28688536 0.77 MAP3K14 (0.47) ELANEMAP3K14CDC7CDK2ROCK1
SCHEMBL11970844 0.77 MAP3K14 (0.42) MAP3K14CDC7CDK2ROCK1PDGFRA
SCHEMBL11970555 0.76 DYRK3 (0.50) MAP3K14CDC7CDK2ROCK1ALDH1A1
SCHEMBL11970947 0.76 MAP3K14 (0.50) MAP3K14CDC7CDK2ROCK1PDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150038460-A1 6,5-Heterocyclic Propargylic Alcohol Compounds and Uses Therefor GENENTECH, INC. (US) 2015-02-05 — — US disclosed
US-20150038460-A1 6,5-Heterocyclic Propargylic Alcohol Compounds and Uses Therefor GENENTECH, INC. (US) 2015-02-05 — — US disclosed
US-20150038460-A1 6,5-Heterocyclic Propargylic Alcohol Compounds and Uses Therefor GENENTECH, INC. (US) 2015-02-05 — — US disclosed
US-8901313-B2 6,5-heterocyclic propargylic alcohol compounds and uses therefor GENENTECH, INC. (US) 2014-12-02 — — US disclosed
US-8901313-B2 6,5-heterocyclic propargylic alcohol compounds and uses therefor GENENTECH, INC. (US) 2014-12-02 — — US disclosed
US-8901313-B2 6,5-heterocyclic propargylic alcohol compounds and uses therefor GENENTECH, INC. (US) 2014-12-02 — — US disclosed
EP-2686314-A1 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR F.HOFFMANN-LA ROCHE AG (CH) 2014-01-22 — — EP disclosed
WO-2012123522-A1 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR F. HOFFMANN-LA ROCHE AG (CH) 2012-09-20 — — WO disclosed
WO-2012123522-A1 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR F. HOFFMANN-LA ROCHE AG (CH) 2012-09-20 — — WO disclosed
US-20120214762-A1 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR GENENTECH, INC. (US) 2012-08-23 — — US disclosed
US-20120214762-A1 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR GENENTECH, INC. (US) 2012-08-23 — — US disclosed
US-20120214762-A1 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR GENENTECH, INC. (US) 2012-08-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214762-A1 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR NFKB1, NFRKB, NFKBIA ELANE 3762/4885MAP3K14 519/4885CDC7 4283/4885
US-20150038460-A1 6,5-Heterocyclic Propargylic Alcohol Compounds and Uses Therefor NFKB1, NFRKB, NFKBIA ELANE 3762/4885MAP3K14 519/4885CDC7 4283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback